Novo Nordisk Pharmatech reports expanded sales and product pipeline

Koege, Denmark: – World-leading insulin and quaternary compounds (Quats) specialist Novo Nordisk Pharmatech A/S has released its Annual Report for year ending December 31, 2021.

The report shows higher than expected external sales, maintenance of net profit, expanded production capabilities, and a healthy new product pipeline.

Insulin growth

External sales exceeding expectations were driven by the increased sales of technical insulin sustained throughout 2021 due to organic growth within the biopharmaceutical industry and increased demand due to COVID-19-related activities.

The Quats product group, on the other hand, declined both due to stock building in 2020 at large customers, as well as increased competition.

Expanded sales representation and product pipeline

During 2021 the company established a new sales office in the US. Novo Nordisk Pharmatech now has presence in Copenhagen, Singapore, and the east and west coasts of the USA, making it optimally geographically positioned to support its customers worldwide.

In R&D, the company developed its pipeline for resin and enzyme-related products. In particular, NNP developed a new affinity resin for parent company Novo Nordisk that is now going into production, It also initiated a new application study to show the superior properties of its mixed mode resins.

Production and quality

In 2021, Novo Nordisk Pharmatech invested in the rebuilding of a multi-product purification plant for specialty process enzymes. This facility is an important cornerstone of its growth strategy that aims for a portfolio of specialty enzymes supporting the external market for advanced therapy medicinal products (ATMPs). To stock this pipeline, NNP also signed a collaboration agreement with Novozymes.

Novo Nordisk Pharmatech’s quality performance continued at a very high level in 2021 where we managed to host 22 audits, including a DMA inspection.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S is a global and leading manufacturer of pharmaceutical aids for the pharmaceutical and biopharmaceutical industries. The company specializes in producing quaternary ammonium compounds (Quats) used as active pharmaceutical ingredients (APIs) and excipients as well as delivering Recombinant Insulin for use in cell culture media to enhance cell growth and viability, and productivity.

Novo Nordisk Pharmatech A/S helps the world´s largest pharmaceutical and biopharmaceutical industries reduce their risk for raw materials by using pharma-grade products with a high level of consistency, purity, quality, and reliability.

Novo Nordisk Pharmatech A/S was established in 1949 as Ferrosan Fine Chemicals and acquired by Novo Nordisk in 1986. The company is operating as a division of Novo Nordisk A/S from Køge, south of Copenhagen.

You can learn more about Novo Nordisk Pharmatech at novonordiskpharmatech.com.

Resources

Click on Novo Nordisk Pharmatech Annual Report 2021 for further information.